Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorHenan Cancer Hospital
About this trial
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of Rituximab, Lenalidomide combined with high-dose Methotrexate and Temozolomide (RL-MT) in the first-line treatment for patients with primary central nervous system lymphoma.
Eligibility criteria
Qualifiers
Age between 18 to 70 years old (including 18 and 70)
Diagnosed as primary central nervous system lymphoma (limited to the brain, spinal cord, meninges and eyeballs, without involvement of other parts)
Having not received anti-tumor therapy before enrollment (except for tumor resection and biopsy and the use of glucocorticoids to reduce central nervous system symptoms)
Having at least one measurable lesions
Disqualifiers
Diagnosed as secondary central nervous system lymphoma
Diagnosed as CD20 negative large B cell primary central nervous system lymphoma
Active malignant tumor need be treated at the same time
Other malignant tumor history
Trial design
Treatments tested in this trial
- Rituximab
- Lenalidomide
- Methotrexate
- Temozolomide
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov